

Orazio Caffo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1421898/orazio-caffo-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

199
papers

3,842
citations

31
h-index

55
g-index

211
ext. papers

4,284
ext. citations

3.9
avg, IF

4.72
L-index

#	Paper	IF	Citations
199	A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training-Validation Trial.. <i>Journal of Medical Internet Research</i> , 2022 , 24, e27349	7.6	0
198	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. <i>European Urology</i> , 2022 ,	10.2	2
197	Rheumatic immune- and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: a systematic review and meta-analysis.. <i>Joint Bone Spine</i> , 2022 , 105403	2.9	
196	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series.. <i>World Journal of Clinical Oncology</i> , 2021 , 12, 1037-1046	2.5	
195	Severe acute respiratory syndrome coronavirus 2 infection in patients with prostate cancer: A critical review. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 167, 103491	7	3
194	Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2021 , 17, 807-815	3.6	
193	Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 162, 103351	7	8
192	Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without Ra. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021 , 36, 391-396	3.9	
191	To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today?. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 389-400	3.5	0
190	Management of brain metastases from lung cancer in the era of immunotherapy: a review of the literature. <i>Future Oncology</i> , 2021 , 17, 597-609	3.6	1
189	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. <i>Targeted Oncology</i> , 2021 , 16, 625-632	5	2
188	Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab. <i>Immunotherapy</i> , 2021 , 13, 1093-1103	3.8	0
187	Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. <i>European Journal of Cancer</i> , 2021 , 155, 56-63	7.5	3
186	Equity in Drug Accessibility: The Surprising Case of Treatments for Metastatic Castration-sensitive Prostate Cancer in European Countries. <i>European Urology Oncology</i> , 2021 , 4, 1011-1011	6.7	1
185	Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020 , 140, 140-146	7.5	12
184	Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. <i>Cancers</i> , 2020 , 12,	6.6	5
183	Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2

182	Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 2633-2638	8.8	3
181	Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 69-76.e4	3.3	6
180	Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database. <i>European Journal of Cancer</i> , 2020 , 125, 153-163	7.5	3
179	On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. <i>Annals of Oncology</i> , 2020 , 31, 1415-1416	10.3	21
178	The prognostic value of pain in castration-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 654-660	6.2	1
177	Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. <i>European Urology Oncology</i> , 2020 , 3, 176-182	6.7	10
176	Treatment sequencing in oncology: balancing clinical trial and real-world evidence. <i>Future Oncology</i> , 2019 , 15, 2887-2889	3.6	4
175	Adjuvant chemotherapy in resected bile duct cancer: A systematic review and meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 143, 124-129	7	12
174	Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2019 , 15, 1115-1123	3.6	5
173	Multidisciplinary teams for the proper management of patients with genitourinary tumors: When topics set scientific societies' agenda. <i>Tumori</i> , 2019 , 105, 161-167	1.7	1
172	Sequencing strategies in the new treatment landscape of prostate cancer. <i>Future Oncology</i> , 2019 , 15, 2967-2982	3.6	4
171	Sequencing chemotherapy and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (UC): Meet-Uro1 study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e16013-e16013	2.2	1
170	A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 148-148	2.2	6
169	PAzopanib as first line in METastatic RCC patients: A Real-world Italian experience (PAMERIT study) Preliminary results.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 611-611	2.2	
168	A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5050-5050	2.2	
167	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2019 , 12,	6.6	14
166	Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document. <i>Cancers</i> , 2019 , 11,	6.6	1
165	Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019 , 107, 186-195	7.5	9

164	Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e187-e194	3.3	9
163	Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHARTED and LATITUDE era. <i>Cancer Treatment Reviews</i> , 2019 , 74, 35-42	14.4	20
162	Association among metabolic syndrome, inflammation, and survival in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 240.e1-240.e11	2.8	13
161	Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2018 , 97, 41-48	7.5	8
160	Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 165-175.e2	3.3	27
159	Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review. <i>Future Oncology</i> , 2018 , 14, 431-442	3.6	10
158	Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. <i>Clinical Lung Cancer</i> , 2018 , 19, 93-104	4.9	31
157	De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. <i>Cancer Treatment Reviews</i> , 2018 , 70, 67-74	14.4	26
156	Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. <i>European Urology Oncology</i> , 2018 , 1, 467-475	6.7	18
155	Sequencing radium 223 (RA223) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the daily practice: Preliminary results from a retrospective study in Italian centers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 322-322	2.2	1
154	Impact of new agents (NAs) on survival of metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A single-Institution retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 323-323 ^{2.2}	2.2	5
153	Treatment with combined dabrafenib and trametinib in -mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation. <i>Drugs in Context</i> , 2018 , 7, 212515	5.2	8
152	Treatment and clinical outcomes of very elderly (≥80 yrs) metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A single-institution retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 327-327	2.2	
151	Safety and efficacy of abiraterone acetate (AA) in patients aged 75 or more with metastatic castration-resistant prostate cancer (mCRPC) in both pre-chemotherapy or post-chemotherapy settings: Real-life experience from thirteen Italian centers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 209-209	2.2	
150	Survival outcomes from a cumulative analysis from worldwide observational studies on sequential use of new agents (NAs) in metastatic castration-resistant prostate cancer (mCRPC) (CASTOR study).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5026-5026	2.2	
149	Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?. <i>Frontiers in Cell and Developmental Biology</i> , 2018 , 6, 71	5.7	8
148	Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. <i>Future Oncology</i> , 2018 , 14, 2691-2699	3.6	2
147	Cardiovascular toxicities of systemic treatments of prostate cancer. <i>Nature Reviews Urology</i> , 2017 , 14, 230-243	5.5	12

146	First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e609-e614	3.3	30
145	Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2017 , 77, 1012-1019	4.2	4
144	Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 899-908	4	5
143	Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 113, 43-51	7	26
142	Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3189-3197	2.2	168
141	The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 ,	3.3	19
140	Cardiovascular toxicities of systemic treatments of prostate cancer: is oestrogen to the rescue?. <i>Nature Reviews Urology</i> , 2017 , 14, 1	5.5	6
139	Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer: everyday clinical practice in a single centre. <i>Anti-Cancer Drugs</i> , 2017 , 28, 654-659	2.4	2
138	Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5030-5030	2.2	3
137	Patients with metastatic castration-resistant prostate cancer (mCRPC) are primary resistant (PR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e585-e585	2.2	
136	Patients with metastatic castration-resistant prostate cancer (mCRPC) who are long-term responders (LTR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 254-254	2.2	
135	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in pts with metastatic castration-resistant prostate cancer (mCRPC) receiving a new agent (NA)- based third-line treatment: Final results from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 230-230	2.2	
134	Efficacy of cabazitaxel (CABA) rechallenge in heavily-treated patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5033-5033	2.2	1
133	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)- based third line treatment: Final results from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16521-e16521	2.2	
132	Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions. <i>Clinical Interventions in Aging</i> , 2017 , 12, 19-28	4	6
131	Could Steroidal Abiraterone Metabolites Possibly Explain Abiraterone Withdrawal Syndrome?. <i>European Urology</i> , 2016 , 70, 898-899	10.2	4
130	Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation. <i>Prostate International</i> , 2016 , 4, 54-5	3.4	
129	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016 , 12, 493-502	3.6	6

128	Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers. <i>Future Oncology</i> , 2016 , 12, 333-42	3.6	22
127	BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study. <i>Lung Cancer</i> , 2016 , 95, 73-81	5.9	14
126	Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 48-55	3.3	14
125	Cabazitaxel vs docetaxel in chemotherapy-naïve (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5006-5006	2.2	27
124	First-line pazopanib in non-clear cell renal carcinoma: The Italian retrospective multicenter PANORAMA study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16081-e16081	2.2	2
123	Long-term outcomes and predictive factors in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) showing abiraterone withdrawal syndrome (AWS) after docetaxel (DOC) treatment.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 324-324	2.2	5
122	Predictors of long-term response to abiraterone in patients with metastatic castration-resistant prostate cancer: a retrospective cohort study. <i>Oncotarget</i> , 2016 , 7, 40085-40094	3.3	13
121	Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality?. <i>Current Drug Targets</i> , 2016 , 17, 1301-8	3	5
120	Does abiraterone withdrawal syndrome (AWS) exist also in metastatic castration-resistant prostate cancer (mCRPC) first-line setting?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 344-344	2.2	
119	Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 210-210	2.2	
118	Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) after a long-term disease control (LTDC) with abiraterone acetate (AA) or enzalutamide (ENZ) post docetaxel (DOC): Preliminary results from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 325-325	2.2	
117	Clinicians' attitudes and preferences in choosing the first line drug for metastatic castration resistant prostate cancer (mCRPC): Preliminary results from a multicenter Italian study after the introduction of abiraterone acetate (AA) in the clinical practice.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 326-326	2.2	
116	Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 231-231	2.2	
115	Is metronomic cyclophosphamide (mCTX) a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the era of new agents (NAs)? A retrospective multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 326-326	2.2	
114	Very early PSA response to abiraterone in mCRPC patients: A novel prognostic factor to predict overall survival.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 219-219	2.2	
113	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)-based third line treatment: Preliminary results from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 211-211	2.2	
112	Prognostic role of body mass index (BMI) in patients with metastatic castration resistant prostate cancer (mCRPC) receiving chemotherapy: Preliminary results from a retrospective Italian multicenter study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 342-342	2.2	
111	Assessment of prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) after docetaxel (DOC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16569-e16569	2.2	

110	Splice Variants of Androgen Receptor and Prostate Cancer. <i>Oncology Reviews</i> , 2016 , 10, 297	4.3	5
109	Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer. <i>PLoS ONE</i> , 2016 , 11, e0158952	3.7	39
108	Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival. <i>Frontiers in Pharmacology</i> , 2016 , 7, 123	5.6	26
107	Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. <i>Frontiers in Pharmacology</i> , 2016 , 7, 376	5.6	93
106	Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016 , 20, 255-63	4.5	9
105	Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials. <i>Radiotherapy and Oncology</i> , 2016 , 121, 193-198	5.3	25
104	Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 265.e15-21	2.8	6
103	Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015 , 11, 965-73	3.6	9
102	Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015 , 11, 2881-91	3.6	10
101	Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 498-506	7	40
100	Gastrointestinal metastases from prostate cancer: a review of the literature. <i>Future Oncology</i> , 2015 , 11, 691-702	3.6	2
99	Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?. <i>World Journal of Urology</i> , 2015 , 33, 1079-85	4	27
98	Reply to Kevin Lu's Letter to the Editor re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>Eur Urol</i> 2015;68:147-53. <i>European Urology</i> , 2015 , 68, e132-3	10.2	1
97	Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2015 , 115, 744-52	5.6	40
96	Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. <i>BJU International</i> , 2015 , 115, 764-71	5.6	16
95	Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2015 , 75, 1329-38	4.2	16
94	Impact of post-implant dosimetric parameters on the quality of life of patients treated with low-dose rate brachytherapy for localised prostate cancer: results of a single-institution study. <i>Radiation Oncology</i> , 2015 , 10, 130	4.2	5
93	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015 , 68, 147-53	10.2	62

92	Impact of new agents (NAs) on post-docetaxel (DOC) survival of octogenarians with metastatic castration resistant prostate cancer (mCRPC) patients (pts): Results of an Italian multicenter retrospective study (DELPHI study).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16017-e16017	2.2	1
91	High neutrophil to lymphocyte ratio (NLR) persistence during enzalutamide to predict poor clinical outcome in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16059-e16059	2.2	2
90	Sequential use of new agents (NAs) after docetaxel (DOC) first line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A pooled-analysis of the published studies.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 258-258	2.2	4
89	Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) showing a primary resistance (PRes) to NAs-based second line therapy after docetaxel (DOC): Preliminary results from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 258-258	2.2	
88	Concurrent gemcitabine (GEM) and radiotherapy (XRT) as organ-sparing treatment for muscle-infiltrating bladder cancer (MIBC): Preliminary results of a patient-based cumulative analysis of seven phase I-II trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 306-306	2.2	
87	Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 213-213	2.2	
86	Primary resistance to abiraterone acetate (AA) after docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC): A multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 206-206	2.2	
85	Visceral disease site to predict clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA): Results of the Italian compassionate use named patient program (NPP).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16045-e16045	2.2	
84	Neoadjuvant chemotherapy (NC) in invasive breast cancer (IBC) subtypes: Outcomes according to pathological complete response (pCR) and proliferation index (PI) of residual tumor (RT).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e12027-e12027	2.2	
83	Prognostic factors in muscle-infiltrating bladder cancer (MIBC) treated with an organ-sparing treatment with concurrent gemcitabine (GEM) and radiotherapy (XRT): Results of a patient-based cumulative analysis of seven phase I-II trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15529-e15529	2.2	
82	Is it possible that one patient may again experience a response to abiraterone acetate withdrawal during an abiraterone acetate rechallenge?. <i>European Urology</i> , 2014 , 66, 179-80	10.2	4
81	Unusual small bowel metastatic localization in a castration-resistant prostate cancer patient. <i>Clinical Practice (London, England)</i> , 2014 , 11, 559-562	3	1
80	Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide. <i>Future Oncology</i> , 2014 , 10, 985-93	3.6	18
79	Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 594-600	4	25
78	Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 733-7	8.9	24
77	Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 312-6	3.3	18
76	Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A multicenter Italian experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5089-5089	2.2	3
75	Weekly paclitaxel (wPCT) for pretreated patients (pts) with advanced non-small cell lung cancer (aNSCLC): Updated data from a single institution experience in the daily clinical practice.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19143-e19143	2.2	0

74	Safety and clinical outcome of a cohort of patients (pts) with castration resistant prostate cancer (CRPC) treated with abiraterone acetate (AA) in a named patient program (NPP): Updated results of a retrospective study from an Italian cooperative group.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 253-253	2.2	1
73	Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 92-92	2.2	2
72	Volume reduction and metabolic response of primary prostate cancer to enzalutamide (ENZ) : A metabolic evaluation by 18F-fluorocholine-positron emission tomography/computerized tomography (18F-FCH PET/CT) in castration resistant prostate cancer (CRPC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16056-e16056	2.2	
71	Potential value of rapid prostate-specific antigen (PSA) decline, in identifying primary resistance (PRes) to abiraterone acetate (AA) and enzalutamide (ENZ), in pre-treated castration resistant prostate cancer (CRPC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16044-e16044	2.2	
70	Metabolic response to enzalutamide (ENZ), assessed by choline positron emission tomography (cPET), in castration resistant prostate cancer (CRPC) patients (pts): Updated results of a monoinstitutional prospective study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16043-e16043	2.2	
69	Looking to possible predictive factors of primary resistance to abiraterone acetate (AA) and enzalutamide (ENZ) in pretreated patients (pts) with castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 248-248	2.2	
68	Clinical outcomes of patients (pts) age 60 or younger treated with docetaxel (DOC) for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (CYCLOP study).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 214-214	2.2	
67	Metabolic response by choline positron emission tomography (cPET) to enzalutamide (ENZ) in castration-resistant prostate cancer (CRPC) patients (pts): Preliminary results of a monoinstitutional prospective study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 76-76	2.2	
66	Metabolic and prostate-specific antigen response after abiraterone acetate withdrawal: a new clinical scenario for castration-resistant prostate cancer?. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, e10-4	3.3	5
65	Trimodality treatment in the conservative management of infiltrating bladder cancer: a critical review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 86, 176-90	7	12
64	An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 1037-51	5.5	9
63	Frequency of brain metastases from prostate cancer: an 18-year single-institution experience. <i>Journal of Neuro-Oncology</i> , 2013 , 111, 163-7	4.8	16
62	Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: results from a phase II study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 180-6	2.8	4
61	Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer. <i>Urology</i> , 2013 , 82, 1090-3	1.6	21
60	Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 90-90	2.2	
59	Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 208-208	2.2	
58	Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society of Medical Oncology (AIOM). <i>Tumori</i> , 2013 , 99, 35-8	1.7	
57	A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 369-75	3.5	2

56	Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era. <i>Journal of Neuro-Oncology</i> , 2012 , 107, 191-6	4.8	31
55	Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors. <i>Urology</i> , 2012 , 79, 644-9	1.6	43
54	Brain metastases from prostate cancer: an emerging clinical problem with implications for the future therapeutic scenario. <i>Future Oncology</i> , 2012 , 8, 1585-95	3.6	11
53	Conservative treatment of breast ductal carcinoma in situ: results of an Italian multi-institutional retrospective study. <i>Radiation Oncology</i> , 2012 , 7, 177	4.2	11
52	Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial. <i>BJU International</i> , 2011 , 108, 1825-32	5.6	17
51	Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: Long-term cumulative results of 2 prospective single-institution studies. <i>Cancer</i> , 2011 , 117, 1190-6	6.4	25
50	Radiochemotherapy for Non Small Cell Lung Cancer. <i>Current Drug Therapy</i> , 2010 , 5, 180-191	0.7	
49	Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. <i>Lung Cancer</i> , 2010 , 68, 264-8	5.9	86
48	Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010 , 28, 152-6	2.8	16
47	Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2010 , 20, 953-7	3.5	5
46	Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 1197-202	3.5	10
45	Development and daily use of an electronic oncological patient record for the total management of cancer patients: 7 years' experience. <i>Annals of Oncology</i> , 2009 , 20, 349-52	10.3	19
44	Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment. <i>European Urology Supplements</i> , 2009 , 8, 738-746	0.9	4
43	Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. <i>BJU International</i> , 2008 , 102, 1080-5	5.6	28
42	Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2008 , 43, 216-23	2.2	21
41	Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 221-9	8.9	38
40	Prospective evaluation of quality of life after interstitial brachytherapy for localized prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 66, 31-7	4	18
39	A Phase II Study of Liposomal Doxorubicin in Recurrent Epithelial Ovarian Carcinoma. <i>Tumori</i> , 2004 , 90, 556-561	1.7	10

38	A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. <i>British Journal of Cancer</i> , 2004 , 91, 1996-2004	8.7	151
37	Pain and quality of life after surgery for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2003 , 80, 39-48	4.4	121
36	Physical side effects and quality of life during postoperative radiotherapy for uterine cancer. Prospective evaluation by a diary card. <i>Gynecologic Oncology</i> , 2003 , 88, 270-6	4.9	12
35	High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. <i>Cancer</i> , 2003 , 98, 474-83	6.4	183
34	Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 57, 1310-6	4	37
33	Pain after quadrantectomy and radiotherapy for early-stage breast cancer: incidence, characteristics and influence on quality of life. Results from a retrospective study. <i>Oncology</i> , 2003 , 65, 23-8	3.6	45
32	Prognostic value of thymidine phosphorylase expression in breast carcinoma. <i>International Journal of Cancer</i> , 2002 , 97, 512-7	7.5	28
31	Evaluation of toxicity and quality of life using a diary card during postoperative radiotherapy for rectal cancer. <i>Diseases of the Colon and Rectum</i> , 2002 , 45, 459-65; discussion 465-7	3.1	12
30	The Role of Brachytherapy in the Management of Oropharyngeal Carcinomas: The Trento Experience. <i>Tumori</i> , 2002 , 88, 137-141	1.7	5
29	Quality of life after radiotherapy for early-stage testicular seminoma. <i>Radiotherapy and Oncology</i> , 2001 , 59, 13-20	5.3	11
28	Radiosensitization with chemotherapeutic agents. <i>Lung Cancer</i> , 2001 , 34 Suppl 4, S81-90	5.9	46
27	Quality of Life in Patients with Early Stage Breast Carcinoma Treated with Conservation Surgery and Radiotherapy. An Italian Monoinstitutional Study. <i>Tumori</i> , 2001 , 87, 78-84	1.7	15
26	p27kip1 expression in breast carcinomas: An immunohistochemical study on 512 patients with long-term follow-up. <i>International Journal of Cancer</i> , 2000 , 89, 236-241	7.5	55
25	Concurrent adjuvant chemotherapy and immediate breast reconstruction with skin expanders after mastectomy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2000 , 60, 267-75	4.4	44
24	Biological characterisation of superficial bladder cancer by bivariate cytokeratin 7/DNA analysis, flow cytometric assessment of MIB- 1, and an immunohistochemical study. <i>Analytical Cellular Pathology</i> , 2000 , 21, 21-33		3
23	Ocular metastases from breast carcinoma: A multicentric retrospective study. <i>Oncology Reports</i> , 2000 , 7, 761-5	3.5	29
22	p27kip1 expression in breast carcinomas: An immunohistochemical study on 512 patients with long-term follow-up 2000 , 89, 236		3
21	Evaluation of sexual life after orchidectomy followed by radiotherapy for early-stage seminoma of the testis. <i>BJU International</i> , 1999 , 83, 462-8	5.6	32

20	Subclinical Ductal Carcinoma in Situ of the Breast: Treatment with Conservative Surgery and Radiotherapy. <i>Tumori</i> , 1999 , 85, 488-493	1.7	9
19	Quality of life in patients with ductal carcinoma in situ of the breast treated with conservative surgery and postoperative irradiation. <i>Breast Cancer Research and Treatment</i> , 1999 , 54, 109-15	4.4	26
18	p21 expression in colorectal carcinomas: a study on 103 cases with analysis of p53 gene mutation/expression and clinic-pathological correlations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1999 , 435, 559-65	5.1	17
17	Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy. <i>Lancet, The</i> , 1999 , 353, 1310-4	4.0	26
16	Bax immunohistochemical expression in breast carcinoma: a study with long term follow-up. <i>International Journal of Cancer</i> , 1998 , 79, 13-8	7.5	37
15	Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer. <i>Lung Cancer</i> , 1998 , 22, 31-8	5.9	31
14	Tissue carcinoembryonic antigen and oestrogen receptor status in breast carcinoma: an immunohistochemical study of clinical outcome in a series of 252 patients with long-term follow-up. <i>British Journal of Cancer</i> , 1998 , 77, 1661-8	8.7	11
13	Ten-year results of treatment of ductal carcinoma in situ (DCIS) of the breast with conservative surgery and radiotherapy. <i>European Journal of Cancer</i> , 1997 , 33, 1559-65	7.5	28
12	Cytometric DNA analysis and prognostic biomarkers in breast carcinoma. Expression of P53 product in the different ploidy classes. <i>Analytical Cellular Pathology</i> , 1997 , 15, 31-45		10
11	Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. <i>International Journal of Cancer</i> , 1997 , 74, 171-4	7.5	57
10	Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. <i>Annals of Oncology</i> , 1996 , 7, 695-703	10.3	42
9	Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. <i>Human Pathology</i> , 1996 , 27, 1149-55	3.7	82
8	p21WAF1 and p53 immunohistochemical expression in breast carcinoma may predict therapeutic response to adjuvant treatment. <i>European Journal of Cancer</i> , 1996 , 32A, 2182-3	7.5	8
7	p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. <i>British Journal of Cancer</i> , 1996 , 74, 208-15	8.7	96
6	Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire. <i>Cancer</i> , 1996 , 78, 1089-97	6.4	76
5	Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma--results of a multiparametric study. <i>Breast Cancer Research and Treatment</i> , 1995 , 36, 205-17	4.4	95
4	Long-term cosmetic outcome and toxicity in patients treated with quadrantectomy and radiation therapy for early-stage breast cancer. <i>Oncology</i> , 1995 , 52, 177-81	3.6	40
3	Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. <i>Journal of Clinical Oncology</i> , 1994 , 12, 2094-101	2.2	137

2	c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma--an immunocytochemical study. <i>European Journal of Cancer</i> , 1994 , 30A, 16-22	7.5	65
1	Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. <i>Journal of Clinical Oncology</i> , 1994 , 12, 454-66	2.2	395